↓ Skip to main content

The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma: a Multi-insti…

Overview of attention for article published in this source, May 2014
Altmetric Badge

Mentioned by

twitter
1 X user
patent
1 patent

Citations

dimensions_citation
81 Dimensions

Readers on

mendeley
76 Mendeley
Title
The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma: a Multi-institutional NCI-Sponsored Trial
Published by
Springer Nature, May 2014
DOI 10.1007/s12672-014-0182-1
Pubmed ID
Authors

Antonio M. Lerario, Francis P. Worden, Carole A. Ramm, Elizabeth A. Hasseltine, Walter M. Stadler, Tobias Else, Manisha H. Shah, Edem Agamah, Krishna Rao, Gary D. Hammer

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 1%
Unknown 75 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 10 13%
Student > Bachelor 9 12%
Student > Doctoral Student 9 12%
Researcher 8 11%
Student > Master 7 9%
Other 9 12%
Unknown 24 32%
Readers by discipline Count As %
Medicine and Dentistry 21 28%
Agricultural and Biological Sciences 6 8%
Nursing and Health Professions 5 7%
Biochemistry, Genetics and Molecular Biology 3 4%
Psychology 3 4%
Other 8 11%
Unknown 30 39%